Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

Table 1 Genotype and therapeutic response

	Baseline Frequency		Association between SNPs and pCR
SNP	Geno-type	No. (%)	Variant allele group^a vsmajor homozygote	No pCR/pCR (No.)	OR	95% CI	p
XRCC1 Arg399Gln (rs25487)	AA	12 (20)
	AG	19 (32)	AA or AG	29/2
	GG	29 (48)	GG	21/8	5.37	0.94-57.0	0.062
XRCC2 5' flank (rs6464268)	GG	1 (2)
	GA	16 (27)	GG or GA	13/4
	AA	43 (72)	AA	37/6	0.53	0.11-2.99	0.59
ERCC1 3' flank (rs3212986)	TT	0
	GT	22 (37)	GT	17/5
	GG	38 (63)	GG	33/5	0.52	0.10-2.60	0.54
XPD Lys751Gln (rs13181)	GG	8 (13)
	GT	29 (48)	GG or GT	30/7
	TT	23 (38)	TT	20/3	0.64	0.10-3.3	0.83
XPD Asp312Asn (rs1799793)	AA	7 (12)
	AG	28 (47)	AA or AG	28/7
	GG	25 (42)	GG	22/3	0.55	0.082-2.77	0.65

CI, confidence interval; OR, odds ratio for non-pCR of variant allele group as compared to the major homozygote; pCR, complete pathologic response; SNP, single nucleotide polymorphism.
^a The variant allele group consists of the variant allele homozygote and heterozygote in combination.

ISSN: 1471-2407